AU2023248685A1 - Combination therapy for treating cancer - Google Patents

Combination therapy for treating cancer Download PDF

Info

Publication number
AU2023248685A1
AU2023248685A1 AU2023248685A AU2023248685A AU2023248685A1 AU 2023248685 A1 AU2023248685 A1 AU 2023248685A1 AU 2023248685 A AU2023248685 A AU 2023248685A AU 2023248685 A AU2023248685 A AU 2023248685A AU 2023248685 A1 AU2023248685 A1 AU 2023248685A1
Authority
AU
Australia
Prior art keywords
azd5305
pharmaceutically acceptable
acceptable salt
darolutamide
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023248685A
Other languages
English (en)
Inventor
Mark R ALBERTELLA
Jessica S BROWN
Sabina Chiara Cosulich
Elisabetta LEO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2023248685A1 publication Critical patent/AU2023248685A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023248685A 2022-04-07 2023-04-06 Combination therapy for treating cancer Pending AU2023248685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362612P 2022-04-07 2022-04-07
US63/362,612 2022-04-07
PCT/EP2023/059126 WO2023194528A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
AU2023248685A1 true AU2023248685A1 (en) 2024-11-14

Family

ID=86185292

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023248685A Pending AU2023248685A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Country Status (11)

Country Link
US (1) US20250235448A1 (https=)
EP (1) EP4504180A1 (https=)
JP (1) JP2025511401A (https=)
KR (1) KR20240170956A (https=)
CN (1) CN118973572A (https=)
AU (1) AU2023248685A1 (https=)
CA (1) CA3254948A1 (https=)
IL (1) IL316016A (https=)
MX (1) MX2024012368A (https=)
TW (1) TW202404593A (https=)
WO (1) WO2023194528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026021478A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
MX2024012368A (es) 2024-11-08
CN118973572A (zh) 2024-11-15
IL316016A (en) 2024-11-01
TW202404593A (zh) 2024-02-01
US20250235448A1 (en) 2025-07-24
EP4504180A1 (en) 2025-02-12
JP2025511401A (ja) 2025-04-15
KR20240170956A (ko) 2024-12-05
CA3254948A1 (en) 2023-10-12
WO2023194528A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
TW202425976A (zh) 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2023194528A1 (en) Combination therapy for treating cancer
US20250213556A1 (en) Combination therapy for treating cancer
KR102005887B1 (ko) 뇌종양의 예방 또는 치료용 약학 조성물
AU2021206140A1 (en) Combination therapy for treating cancer
US20250228847A1 (en) Combination therapy for treating cancer
KR20240055021A (ko) Tead 저해제에 대한 투여 요법
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
TW202600137A (zh) 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제